Update -- cellectar reports financial results for first quarter 2023 and provides a corporate update

Florham park, n.j., may 04, 2023 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended march 31, 2023 and provided a corporate update.

CLRB Ratings Summary

CLRB Quant Ranking